Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Immix Biopharma, Inc. (IMMX)
Company Research
Source: GlobeNewswire
- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that Phase 1/2 interim results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming American Society of Hematology 2025 Annual Meeting (ASH 2025) being held in Orlando, Florida, December 6–9, 2025. ASH 2025 Presentation Details – NXC-201 Title“First 20-patient safety and efficacy data from NEXICART-2, the first U.S. trial of CAR-T in R/R light chain (AL) amyloidosis, NXC-201”Presentation Date/Time (Eastern Time) Presentation Date: December 7, 2025Presentation Time: 5:45 PM - 6:00 PM ETPresentation Abstract Number: abs25-14730Session Name: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epid
Show less
Read more
Impact Snapshot
Event Time:
IMMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMMX alerts
High impacting Immix Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
IMMX
News
- Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch [Yahoo! Finance]Yahoo! Finance
- Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch [Seeking Alpha]Seeking Alpha
- Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 LaunchGlobeNewswire
- Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation ConferenceGlobeNewswire
- Immix Biopharma (NASDAQ:IMMX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
IMMX
Sec Filings
- 12/2/25 - Form EFFECT
- 11/26/25 - Form 8-K
- 11/7/25 - Form 10-Q
- IMMX's page on the SEC website